Logomix is a synthetic biology company developing artificial human cells for new therapeutics based on its genome engineering platform, Geno-Writing™. With Geno-Writing™, Logomix can write large-scale and complex messages into a genome. It will enable therapy developers to write therapeutics sequences to develop new modalities and cure serious diseases such as cancer, neurodegenerative diseases, and genetic diseases under discovery collaborations with biopharma companies.
Location: Japan, Chuo
Employees: 11-50
Total raised: $3.9M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | StartX | startx.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.02.2023 | Seed | $3.9M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Tomoki | Otani | Business D... | linkedin.c... | - | t*********... |